Supreme Court ruling on Fixed Dose Combination product classification and limitation period extension

The Supreme Court did not address the classification issue of a Fixed Dose Combination product due to a Ministry of Health and Family Welfare notification banning its human use. The Court left the classification question open for future determination. Regarding the extended period of limitation, the Court dismissed the Department's claim of wilful mis-declaration by the assessee, noting historical alignment with the Drug Controller General's guidance on the product's therapeutic value. As a result, the Court ruled out the application of Section 11-A and dismissed the appeals, finding no merit and awarding no costs.

---

---

Issues: Classification of product and invocation of extended period of limitation

Classification Issue:
The appeals raised two issues: classification and extended period of limitation regarding a Fixed Dose Combination (FDC) of vitamin B1 B6 and Vitamin B12. The assessee argued the product fell under Chapter Heading 3003.10 as a medicament, while the Department contended it fell under Heading No. 2936.00 for pro-vitamins and vitamins. The Department asserted that specific entries take precedence over general entries, placing the product under Heading 2936.00. However, the Supreme Court did not delve into the classification issue due to a Ministry of Health and Family Welfare notification banning the product for human use. The Court kept the classification question open for future determination.

Extended Period of Limitation Issue:
Regarding the invocation of the extended period of limitation, the Department alleged wilful mis-declaration by the assessee in a show cause notice dated 2-5-2001 under Section 11A of the Central Excise Act, seeking duty for the period from 1-4-1996 to 28-2-1999. The Court noted that historically, manufacturers, including the assessee, considered the FDC to have therapeutic value, supported by a directive from the Drug Controller General. As the assessee's classification aligned with the Drug Controller's guidance, the Court concluded that Section 11-A could not be applied, ruling out wilful mis-declaration. Consequently, the Court dismissed the appeals, finding no merit and awarded no costs.

---